Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins
August 17, 2023 16:05 ET
|
Revolution Medicines, Inc.
Science Report on KRASG12C(ON)-Selective Inhibitors Provides Preclinical Proof-of-Principle for Company's RAS Innovation Engine and Broad Pipeline REDWOOD CITY, Calif., Aug. 17, 2023 (GLOBE...
Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023
August 03, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
[Latest] Global Precision Medicine Market Size/Share Worth USD 189.64 Billion by 2030 at a 11.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 20, 2023 11:30 ET
|
Custom Market Insights
Austin, TX, USA, July 20, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Precision Medicine Market Size, Trends and Insights By Technology (Big data...
Precision Fermentation Market Size Will Grow USD 6,385 Million by 2032
July 18, 2023 08:07 ET
|
Precedence Research
Ottawa, July 18, 2023 (GLOBE NEWSWIRE) -- The precision fermentation market size was valued at USD 1,930 million in 2022. Precision fermentation is a technology that uses microorganisms, such as...
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference
April 13, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 07, 2023 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Commencement of Public Offering of Common Stock
March 01, 2023 16:17 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
February 27, 2023 16:05 ET
|
Revolution Medicines, Inc.
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
February 21, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in Upcoming Investor Conferences
February 02, 2023 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...